 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...214215216217218219220221222223224...235236» |
- Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment change, Trial withdrawal, Trial primary completion date, Combination therapy, Metastases: Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy (clinicaltrials.gov) - Jul 21, 2014
P=N/A, N=0, Withdrawn, Sponsor: City of Hope Medical Center
N=30 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2016 --> Jul 2014
- ||||| Graspa (eryaspase) / PHAXIAM Therap
New P2 trial, Metastases: Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma (clinicaltrials.gov) - Jul 21, 2014
P2, N=90, Not yet recruiting, Sponsor: ERYtech Pharma
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date, Metastases: Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients (clinicaltrials.gov) - Jul 18, 2014
P4, N=1500, Active, not recruiting, Sponsor: Asan Medical Center
N=30 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2016 --> Jul 2014 Trial primary completion date: Apr 2012 --> Jun 2014
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Surgery, Metastases: ADORE: Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer (clinicaltrials.gov) - Jul 18, 2014
P2, N=320, Active, not recruiting, Sponsor: Asan Medical Center
Trial primary completion date: Apr 2012 --> Jun 2014 Trial primary completion date: Aug 2015 --> Jul 2014
- || pegilodecakin (LY3500518) / Eli Lilly
Enrollment change: A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jul 18, 2014
P1, N=135, Recruiting, Sponsor: ARMO BioSciences
Trial primary completion date: Aug 2015 --> Jul 2014 N=45 --> 135
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Enrollment closed, Metastases: Phase I Trial of Combination of FOLFIRI and SOM 230 (clinicaltrials.gov) - Jul 17, 2014
P1, N=18, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
N=45 --> 135 Recruiting --> Active, not recruiting
- ||||| Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment closed, HEOR, Combination therapy, Metastases: AFEQT: Colorectal Cancer Metastatic (clinicaltrials.gov) - Jul 16, 2014
P3, N=200, Active, not recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly
Enrollment change, Metastases: FOCULM: FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 15, 2014
P2, N=138, Recruiting, Sponsor: Sun Yat-sen University
Recruiting --> Active, not recruiting N=106 --> 138
- ||||||| Kepivance (palifermin) / SOBI, Amgen
Trial completion, Metastases: A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer (clinicaltrials.gov) - Jul 15, 2014
P2/3, N=100, Completed, Sponsor: Amgen
N=106 --> 138 Active, not recruiting --> Completed
- | Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment closed: 5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer (clinicaltrials.gov) - Jul 12, 2014
P2, N=39, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- zibotentan (ZD4054) / AstraZeneca
Trial primary completion date, Metastases: FOLFERA: Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 8, 2014
P2, N=111, Completed, Sponsor: Cardiff University
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2012 --> Jul 2011
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
New P2 trial, Combination therapy, Metastases: Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 8, 2014
P2, N=54, Not yet recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
- zibotentan (ZD4054) / AstraZeneca
Trial completion, Trial primary completion date, Metastases: FOLFERA: Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 8, 2014
P2, N=111, Completed, Sponsor: Cardiff University
Trial primary completion date: Apr 2012 --> Jul 2011 Recruiting --> Completed | Trial primary completion date: Apr 2012 --> Jul 2011
- leucovorin calcium / Generic mfg.
Trial primary completion date: A Folinic Acid Intervention for Autism Spectrum Disorders (clinicaltrials.gov) - Jul 1, 2014
P2, N=144, Recruiting, Sponsor: University of Arkansas
Recruiting --> Completed | Trial primary completion date: Apr 2012 --> Jul 2011 Trial primary completion date: Sep 2014 --> Sep 2015
- New P2 trial: A Phase II Study of Neoadjuvant FOLFIRINOX (clinicaltrials.gov) - Jul 1, 2014
P2, N=48, Recruiting, Sponsor: Indiana University
- ||| prexasertib (ACR-368) / Acrivon Therap
Enrollment open, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Jul 1, 2014
P1, N=70, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Sep 2014 --> Sep 2015 Not yet recruiting --> Recruiting
- ||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Oncaspar liquid (pegaspargase) / Servier, lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Clinical: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 1, 2014
P3, N=315, Active, not recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Vectibix (panitumumab) / Amgen
Trial primary completion date: PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors (clinicaltrials.gov) - Jun 27, 2014
P2, N=285, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2013 --> May 2012
- | dilpacimab (ABT-165) / AbbVie
Trial suspension, Metastases: A Study of ABT-165 in Subjects With Solid Tumors (clinicaltrials.gov) - Jun 27, 2014
P1, N=75, Suspended, Sponsor: AbbVie
Trial primary completion date: Feb 2013 --> May 2012 Recruiting --> Suspended
- ||| vanucizumab (RG7221) / Roche, Avastin (bevacizumab) / Roche
Trial initiation date, Metastases: McCAVE: A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 27, 2014
P2, N=150, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Suspended Initiation date: Aug 2015 --> Jun 2014
- || New P2/3 trial: NEPAFOX: Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma (clinicaltrials.gov) - Jun 27, 2014
P2/3, N=126, Not yet recruiting, Sponsor: Krankenhaus Nordwest
- ||||| Zaltrap (ziv-aflibercept IV) / Sanofi
New P2 trial, Metastases: Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR). (clinicaltrials.gov) - Jun 27, 2014
P2, N=80, Not yet recruiting, Sponsor: Centre Oscar Lambret
- ||||| Avastin (bevacizumab) / Roche, Stivarga (regorafenib) / Bayer
New P2 trial, Metastases: PREVIUM: Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab (clinicaltrials.gov) - Jun 27, 2014
P2, N=53, Recruiting, Sponsor: Spanish Cooperative Group for Digestive Tumour Therapy (TTD)
- |||| Avastin (bevacizumab) / Roche, Stivarga (regorafenib) / Bayer
Enrollment open, Metastases: PREVIUM: Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab (clinicaltrials.gov) - Jun 27, 2014
P2, N=53, Recruiting, Sponsor: Spanish Cooperative Group for Digestive Tumour Therapy (TTD)
Initiation date: Aug 2015 --> Jun 2014 Not yet recruiting --> Recruiting
- |||| vanucizumab (RG7221) / Roche, Avastin (bevacizumab) / Roche
Enrollment open, Trial initiation date, Metastases: McCAVE: A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 27, 2014
P2, N=150, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Aug 2015 --> Jun 2014
- |||| duligotuzumab (MEHD7945A) / Roche
Enrollment open, Metastases: Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Jun 27, 2014
P2, N=120, Recruiting, Sponsor: Genentech
Not yet recruiting --> Recruiting | Initiation date: Aug 2015 --> Jun 2014 Active, not recruiting --> Recruiting
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment open: CUFOX: Combining Curcumin With FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer (clinicaltrials.gov) - Jun 27, 2014
P1/2, N=51, Recruiting, Sponsor: University of Leicester
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche
Biomarker: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - Jun 26, 2014
P3, N=3610, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2011 --> Feb 2015
- Trial primary completion date, Metastases: Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jun 22, 2014
P2, N=42, Recruiting, Sponsor: University of Florida
Trial primary completion date: Feb 2011 --> Feb 2015 Trial primary completion date: Jul 2015 --> Dec 2015
- |||| Cyramza (ramucirumab) / Eli Lilly
Trial completion, Metastases: A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer (clinicaltrials.gov) - Jun 22, 2014
P2, N=162, Completed, Sponsor: Eli Lilly and Company
Trial primary completion date: Jul 2015 --> Dec 2015 Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche
Biomarker: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - Jun 22, 2014
P3, N=2389, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=3610 --> 2389 | Trial primary completion date: Feb 2011 --> Feb 2015
- Trial primary completion date: Chemoradiation or Brachytherapy for Rectal Cancer (clinicaltrials.gov) - Jun 19, 2014
P2, N=138, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=3610 --> 2389 | Trial primary completion date: Feb 2011 --> Feb 2015 Trial primary completion date: Feb 2019 --> Oct 2018
- Trial initiation date: Chemoradiation or Brachytherapy for Rectal Cancer (clinicaltrials.gov) - Jun 19, 2014
P2, N=138, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Feb 2019 --> Oct 2018 Initiation date: Feb 2014 --> Oct 2013
- || 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
New P3 trial, Metastases: Rectal Cancer, Adjuvant Chemotherapy, FOLFOX(5-fluorouracil/Leucovorin/Oxaliplatin), Total Mesorectal Excision (clinicaltrials.gov) - Jun 19, 2014
P3, N=1008, Not yet recruiting, Sponsor: Yonsei University
- Enrollment open, Trial initiation date, Trial primary completion date: Chemoradiation or Brachytherapy for Rectal Cancer (clinicaltrials.gov) - Jun 19, 2014
P2, N=138, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Initiation date: Feb 2014 --> Oct 2013 Not yet recruiting --> Recruiting | Initiation date: Feb 2014 --> Oct 2013 | Trial primary completion date: Feb 2019 --> Oct 2018
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date, Metastases: Phase I Trial of Combination of FOLFIRI and SOM 230 (clinicaltrials.gov) - Jun 17, 2014
P1, N=18, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Not yet recruiting --> Recruiting | Initiation date: Feb 2014 --> Oct 2013 | Trial primary completion date: Feb 2019 --> Oct 2018 Trial primary completion date: Aug 2014 --> Aug 2015
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Enrollment change, Trial primary completion date, Metastases: Phase I Trial of Combination of FOLFIRI and SOM 230 (clinicaltrials.gov) - Jun 17, 2014
P1, N=18, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Aug 2014 --> Aug 2015 N=30 --> 18 | Trial primary completion date: Aug 2014 --> Aug 2015
- || Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment change, Combination therapy, Metastases: GP28328: A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jun 15, 2014
P1, N=101, Recruiting, Sponsor: Genentech
N=30 --> 18 | Trial primary completion date: Aug 2014 --> Aug 2015 N=68 --> 101
- || andecaliximab (GS-5745) / Gilead
Trial primary completion date, Combination therapy, Monotherapy, Metastases: Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jun 13, 2014
P1, N=199, Recruiting, Sponsor: Gilead Sciences
N=68 --> 101 Trial primary completion date: Jan 2015 --> Jun 2015
- || andecaliximab (GS-5745) / Gilead
Enrollment change, Combination therapy, Monotherapy, Metastases: Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jun 13, 2014
P1, N=199, Recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Jan 2015 --> Jun 2015 N=104 --> 199
- || Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
New P3 trial: CAIRO5: Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases (clinicaltrials.gov) - Jun 13, 2014
P3, N=640, Not yet recruiting, Sponsor: Dutch Colorectal Cancer Group
- || Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Metastases: Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study) (clinicaltrials.gov) - Jun 4, 2014
P2, N=289, Completed, Sponsor: Merck KGaA
N=104 --> 199 Trial primary completion date: Oct 2012 --> Apr 2014
- |||| Erbitux (cetuximab) / Eli Lilly
Trial completion, Metastases: Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study) (clinicaltrials.gov) - Jun 4, 2014
P2, N=289, Completed, Sponsor: Merck KGaA
Trial primary completion date: Oct 2012 --> Apr 2014 Active, not recruiting --> Completed
- Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Trial initiation date, Combination therapy, Metastases: MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 3, 2014
P1, N=34, Recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Initiation date: Mar 2014 --> Jun 2014
- Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment open, Combination therapy, Metastases: MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 3, 2014
P1, N=34, Recruiting, Sponsor: City of Hope Medical Center
Initiation date: Mar 2014 --> Jun 2014 Not yet recruiting --> Recruiting
- || duligotuzumab (MEHD7945A) / Roche
Trial primary completion date, Metastases: Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Jun 2, 2014
P2, N=135, Active, not recruiting, Sponsor: Genentech
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2015 --> Jun 2015
- Enrollment open: Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer (clinicaltrials.gov) - Jun 1, 2014
P2, N=41, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Jan 2015 --> Jun 2015 Not yet recruiting --> Recruiting
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Biomarker, Enrollment change: Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors (clinicaltrials.gov) - May 29, 2014
P2, N=26, Completed, Sponsor: Vanderbilt University
Not yet recruiting --> Recruiting N=75 --> 26
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Biomarker, Trial completion: Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors (clinicaltrials.gov) - May 29, 2014
P2, N=26, Completed, Sponsor: Vanderbilt University
N=75 --> 26 Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Combination therapy, Metastases: Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab (clinicaltrials.gov) - May 27, 2014
P1, N=140, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Jul 2019 --> May 2014